Immunotherapy for hormone receptor‒positive HER2-negative breast cancer

被引：0

作者：

Fatima Cardoso ^{[1
]}

Kim M. Hirshfield ^{[2
]}

Kimberly A. Kraynyak ^{[2
]}

Konstantinos Tryfonidis ^{[2
]}

Aditya Bardia ^{[3
]}

机构：

[1] Champalimaud Clinical Center/Champalimaud Foundation,Breast Unit

[2] Inc.,Merck & Co.

[3] Jonsson Comprehensive Cancer Center,Department of Medicine, Division of Hematology/Oncology, University of California Los Angeles

来源：

npj Breast Cancer | / 10卷 / 1期

关键词：

D O I：

10.1038/s41523-024-00704-9

中图分类号：

学科分类号：

摘要：

Additional therapies are needed to improve outcomes in patients with hormone receptor–positive/human epidermal growth factor receptor 2–negative breast cancer. Research on the potential role of immunotherapy, particularly programmed cell death protein 1/programmed cell death ligand 1 inhibitors, is rapidly expanding in both the early and metastatic settings with some preliminary evidence suggesting benefit when used as part of combination therapy. Several ongoing phase 3 studies should help define their future role in treating these patients.

引用

共 50 条

[41] Optimal treatment strategies in postmenopausal women with hormone-receptor-positive and HER2-negative metastatic breast cancer
Gligorov, Joseph
Lotz, Jean-Pierre
BREAST CANCER RESEARCH AND TREATMENT, 2008, 112 (Suppl 1) : 53 - 66
[42] Metronomic capecitabine with aromatase inhibitors for patients with metastatic hormone-receptor positive, HER2-negative breast cancer
Abdelmaksoud, Bader A.
Toam, Mostafa M.
Fayed, Alaa A.
BREAST CANCER MANAGEMENT, 2019, 8 (03)
[43] Endocrine therapy for hormone receptor-positive, HER2-negative metastatic breast cancer: extending endocrine sensitivity
Frassoldati, Antonio
Biganzoli, Laura
Bordonaro, Roberto
Cinieri, Saverio
Conte, Pierfranco
De Laurentis, Michelino
Del Mastro, Lucia
Gori, Stefania
Lauria, Rossella
Marchetti, Paolo
Michelotti, Andrea
Montemurro, Filippo
Naso, Giuseppe
Pronzato, Paolo
Puglisi, Fabio
Tondini, Carlo Alberto
FUTURE ONCOLOGY, 2020, 16 (05) : 129 - 145
[44] Effectiveness of platinum-based chemotherapy for hormone receptor-positive HER2-negative metastatic breast cancer
Uratani, Lucas Fernando
Bermejo, Francesco Sansone
Hashizume, Pedro HenriqueShimiti
Bonadio, Renata Colombo
Testa, Laura
CANCER RESEARCH, 2021, 81 (04)
[45] Neoadjuvant chemotherapy in hormone receptor-positive/HER2-negative early breast cancer: When, why and what?
Torrisi, Rosalba
Marrazzo, Emilia
Agostinetto, Elisa
De Sanctis, Rita
Losurdo, Agnese
Masci, Giovanna
Tinterri, Corrado
Santoro, Armando
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2021, 160
[46] Clinical trial data and emerging immunotherapeutic strategies: hormone receptor-positive, HER2-negative breast cancer
Kearney, Matthew R.
McGuinness, Julia E.
Kalinsky, Kevin
BREAST CANCER RESEARCH AND TREATMENT, 2021, 189 (01) : 1 - 13
[47] Protein-protein interaction of HER2 predicts the prognosis of hormone receptor-positive HER2-negative breast cancer
Choi, Hee Jun
Lee, Hong Won
Kim, Sangmin
Yoon, Tae-Young
Kim, Hyunwoo
Lee, Seul
Nam, Seok Jin
Kim, Seok Won
Cho, Sooyoun
Park, Yeon Hee
Lee, Jeong Eon
CANCER RESEARCH, 2020, 80 (04)
[48] Olaparib in hormone receptor-positive, HER2-negative metastatic breast cancer with a somatic BRCA2 mutation
Schwartzberg, Lee S.
Kiedrowski, Lesli A.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2021, 13
[49] Triple negative breast cancer compared to hormone receptor negative/HER2 positive breast cancer
Irfan Cicin
Hakan Karagol
Ufuk Usta
Atakan Sezer
Sernaz Uzunoglu
Rusen Alas-Cosar
Tarkan Yetisyigit
Kazim Uygun
Medical Oncology, 2009, 26 : 335 - 343
[50] Triple negative breast cancer compared to hormone receptor negative/HER2 positive breast cancer
Cicin, Irfan
Karagol, Hakan
Usta, Ufuk
Sezer, Atakan
Uzunoglu, Sernaz
Alas-Cosar, Rusen
Yetisyigit, Tarkan
Uygun, Kazim
MEDICAL ONCOLOGY, 2009, 26 (03) : 335 - 343

← 1 2 3 4 5 →